Clinical Trial Detail

NCT ID NCT02060253
Title Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors New York University School of Medicine
Indications

Her2-receptor positive breast cancer

Therapies

Ganetespib + Paclitaxel + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST